August 29, 2023
Via: Pharma TimesThe ODD will offer clinical development and commercialisation benefits that will strengthen the drug programme Faron Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its bexmarilimab for acute myeloid leukaemia […]
Clinical Trials, Research and Development
August 21, 2023
Via: Biopharm InternationalOn Aug. 21, 2023, Gilead Sciences announced that FDA has placed a partial clinical hold on the company initiating new patients into US studies for magrolimab, an investigational anti-CD47 immunotherapy, to treat acute myeloid leukemia (AML). FDA’s decision follows a […]
Clinical Trials, News, Research and Development
April 28, 2020
Via: BioSpaceMoleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that it is now authorized by the Polish Department of Registration of Medicinal Products known as URPL […]
Cell and Gene Therapy, Industry, News
March 2, 2020
Via: Genetic Engineering and Biotechnology NewsGilead Sciences has agreed to acquire Forty Seven for $4.9 billion cash, the companies said today, in a deal intended to boost the buyer’s immuno-oncology R&D pipeline—anchored by Forty Seven’s lead candidate magrolimab, which generated positive Phase Ib results nearly […]
September 19, 2023
September 14, 2023
September 7, 2023
September 5, 2023
September 20, 2023
September 1, 2023
September 14, 2023
August 30, 2023
Copyright © 2023. All rights reserved
